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Prognostic significance of epidermal growth factor receptor in laryngeal
squamous cel carcinoma
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Summary Epidermal growth factor receptor (EGFR) content was determined by a radioligand receptor assay
in 140 primary laryngeal squamous cell carcinomas (median value of 8.4 fmol mg-1 protein, range 0-
169.9 fmol mg- protein). Cox univariate regression analysis using EGFR as a continuous variable showed
that EGFR levels are directly associated with the risk of death (X2 = 14.56, P-value = 0.0001) and relapse
(x2 =7.77, P-value =0.0053). A significant relationship between EGFR status and survival was observed at the
different arbitrary cut-off values chosen (8, 16 and 20 fmol mg- 1 protein). The cut-off value of 20 fmol mg-'
protein was the best prognostic discriminator. In fact, the 5 year survival was 81% for patients with EGFR-
tumours compared with 25% for patients with EGFR+ tumours (P<0.0001). The 5 year relapse-free survival
was 77% for patients with EGFR- tumours compared with 24% for patients with EGFR+ tumours
(P<0.010). When clinicopathological parameters and EGFR status were examined in the multivariate analysis,
T classification and EGFR status retained an independent prognostic value. In this study we demonstrated that
high EGFR levels single out patients with poor prognosis in laryngeal cancer.
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Laryngeal cancer accounts for 1.2% of all new cases of
malignancy in the United States (Silverberg et al., 1990) with
an incidence of 12 300 cases per year, and accounts for 0.7%
of all cancer deaths.
At present, therapy is determined by age, performance
status, stage of disease and tumour location. However, these
clinical parameters are still inadequate for the prognostic
characterisation of laryngeal cancer, since patients with
identical clinicopathological features may differ widely in
the development of the disease and in response to therapy
(Snow, 1989). Thus, the identification of factors more strictly
related to tumour cell biology may be useful in characterising
patients with a different prognosis. Previous studies have
identified biological factors, such as DNA index and/or
ploidy (Rua et al., 1991; Kearseley et al., 1991), or cell
proliferation markers (Coltrera, 1993), which may predict the
clinical outcome of laryngeal cancer. Moreover, much
attention has been focused on the role of oncogenes, i.e.
p53, c-ras, c-myc (Brennan et al., 1995; Anderson et al., 1992;
Scambia et al., 1994a; Irish and Bernstein, 1993) and EGFR
expression and/or amplification (Irish and Bernstein, 1993;
Miyaguchi et al., 1990; Scambia et al., 1991; Santini et al.,
1991).
The epidermal growth factor/epidermal growth factor
receptor (EGF/EGFR) system may be involved in cell
transformation through different mechanisms, the most
frequent of which are autocrine overproduction of epidermal
growth factor/transforming growth factor alpha (EGF/
TGFa) and overexpression of normal EGFR (by gene
amplification or altered transcriptional mechanisms) (Velu,
1990). Tumours containing high EGFR levels appear to have
a worse prognosis in breast (Sainsbury et al., 1987), ovarian
(Scambia et al., 1992), endometrial (Scambia et al., 1994b),
bladder (Neal et al., 1991) and oesophageal (Ozawa et al.,
1989) cancer.
Although the role of EGFR in the development of the
malignant laryngeal squamous cell phenotype has been
described (Grandis and Tweardy, 1993; Stanton et al.,
1994), the prognostic role of EGFR in laryngeal tumours is
not fully established. A previous study (Dassonville et al.,
1993) reported an independent prognostic role of high EGFR
levels in a series of head and neck cancers. In our preliminary
study, despite the relatively small number of laryngeal
tumours examined and the short follow-up time, EGFR
levels are associated with a more aggressive laryngeal cancer
behaviour (Maurizi et al., 1992). In this study the clinical
significance of EGFR in laryngeal squamous cell carcinoma
was investigated for the first time on a large single institution
patient population with a long follow-up.
Materials and methods
Our study included 140 primary laryngeal cancer patients
admitted to the Department of Otolaryngology of the
Catholic University of Rome. All patients were staged
according to TNM classification (Hermanek and Sobin,
1992) and tumours graded as well (GI), moderately (G2)
and poorly (G3) differentiated. The clinicopathological
features of the patients are listed in Table I.
Tumours were classified as supraglottic, glottic or
transglottic when the extent of disease did not permit
identification of the original site.
Seventy-three patients underwent radical laryngectomy
and sixty-seven had conservative surgery (i.e. cordectomy,
horizontal supraglottic laryngectomy and hemilaryngectomy).
None of the patients received preoperative chemotherapy or
radiotherapy. All the patients with relapse or regional neck
metastasis underwent salvage surgery or irradiation.
EGFR assay
Tissue specimens were frozen on dry ice shortly after surgical
removal and stored at -80°C until processed. A representa-
tive section of specimens was retained for histological
examination, which revealed that most of the cells were
cancer cells.
The membrane fraction and cytosol were prepared as
described elsewhere (lacobelli et al., 1987; Scambia et al.,
1991). The membrane pellet was resuspended in TENG plus
10 mM magnesium chloride. Aliquots of the suspension
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(100 MI1 containing 300 to 500 jug protein) were incubated with
[251I]EGF (NEN Dupont DE Nemours) (3.2 nM) in the
presence or absence of unlabelled EGF (1 gM) for 16 h at
room temperature in a final volume of 400 4l. Binding was
stopped by the addition of 3 ml of TENG plus 0.1% bovine
serum albumin (BSA). Pellets were obtained by centrifugation
at 2000 xg for 20 min at 0°C and counted in a gamma
counter for 1 min. Protein concentration was measured by
the Bradford method (Bradford, 1976). Results were
expressed as fmol per mg of membrane protein (fmol mg-'
protein). Receptor characterisation has been reported else-
where (Scambia et al., 1991).
Table I Distribution of EGFR levels according to clinicopatholo-
gical parameters in 140 primary laryngeal cancer patients
Median Range
No. (fmoles mg-' protein)
Total 140 8.4 0- 169.9
Sex
Males 130 8.3 0- 169.9
Females 10 10.6 0- 149.9
Age
<60 years 46 7.2 0-86.9
60 years 94 9.1 0-169.9
Tumour site
Glottic 13 6.1 0-64.8
Supraglottic 47 8.5 0-169.9
Transglottic 80 8.7 0.5- 164.8
T Classification
1 22 8.8 0-64.8
2 57 7.2 0.3-169.9
3 41 8.3 0-86.9
4 20 14.3 1.1 -164.8
Lymph-node involvement
No 103 7.6 0- 169.9
Yes 37 10.5 2.37- 164.8
Histopathological grading
GI 28 7.5 0-64.8
G2 71 9.1 0-164.8
G3 41 8.4 0- 169.9
Statistical analysis
The Wilcoxon rank sum non-parametric test was used to
analyse the distribution of EGFR levels according to
clinicopathological characteristics. The Cox-Mantel method
was used to evaluate the prognostic role of logarithmically
transformed EGFR values as a continuous variable (Cox,
1972).
Different cut-off values for EGFR were tested in the
survival analysis and arbitrary values of 8, 16 and
20 fmol mg-' protein were chosen. All medians and life
tables were computed using the product-limit estimate by
Kaplan and Meier (1958) and the curves were examined by
means of the log-rank test (Mantel, 1966). Multivariate
analysis was performed by the Cox proportional hazards
model (Cox, 1972). Relapse-free survival (RFS) was
calculated from the date of first surgery to the date of
clinical or pathological local recurrence. Overall survival (OS)
was calculated from the date of first surgery to the date of
death (median follow-up was 49 months, range 2-84
months).
Results
The distribution of EGFR levels in 140 primary laryngeal
cancer patients is shown in Table I. EGFR levels ranged
from 0 to 169.9 fmol mg-' protein, with a median value of
8.4 fmol mg-1 protein. Using arbitrary cut-off values of 8, 16
and 20 fmol mg-' protein, 53%, 26% and 20% of tumours,
respectively, were considered EGFR+. No difference in
EGFR distribution in relation to sex, age, tumour site, T
classification, lymph node involvement or histopathological
grading was observed (Table I). During the follow-up period
local recurrence was observed in 50 cases. At the end of the
study 37 patients had died of cancer. Cox univariate
regression analysis using EGFR as a continuous variable
showed that EGFR levels are directly associated with the risk
of death (2 = 14.56, P-value=0.0001) and relapse (x2=7.77,
P-value =0.0053).
Figure 1 shows the survival curves according to EGFR
status. A significant relationship was found between EGFR
positivity and a shorter survival at the different cut-off values
chosen. The cut-off value of 20 fmol mg-' protein was the
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Figure 1 Survival rate according to EGFR status in 140 primary laryngeal cancer patients: overall survival (37 patients had died),
relapse-free survival (50 patients had local recurrence).
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,)nbest prognostic discriminator. In fact, the 5 year survival was
81% (95% confidence intervals, CI 74-88%) for patients
with EGFR- tumours compared with 25% (95% CI 5-45%)
for patients with EGFR+ tumours (P<0.0001). Similarly, the
relapse-free survival curves shown in Figure 1 demonstrated
that EGFR+ patients have a shorter RFS than EGFR-
patients at different cut-off values tested. At the cut-off value
of 20 fmol mg-1 protein the 5 year relapse-free survival was
77% (95% CI 68-86%) for patients with EGFR- tumours
compared with 24% (95% CI 2-46%) for patients with
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EGFR+ tumours (P<0.010). T classification was also
significantly correlated with survival in the univariate
analysis (Table II).
Table III shows the multivariate analysis of prognostic
variables for survival in laryngeal cancer patients. T
classification and EGFR status are the most important
independent prognostic factors in overall and relapse-free
survival. Moreover, in overall survival, histopathological
grading seems to have an additional role as a prognostic
factor.
Table II Univariate analysis of prognostic variables for survival in 140 primary laryngeal cancer patients
Prognostic variable
Age
<60 years
60 years
Tumour site
Glottic
Supraglottic
Transglottic
T classification
1-2
3-4
Lymph node involvement
No
Yes
Histopathological grading
Gl -G2
G3
EGFR status
<8 fmol mg-' protein
, 8 fmol mg-' protein
EGFR status
< 16 fmol mg 1 protein
> 16 fmol mg-' protein
EGFR status
<20 fmol mg-' protein
,>20 fmol mg-' protein
Overall survival
No. of Five year
patients survival % 95% CI
46
94
13
47
80
78
62
103
37
99
41
66
74
103
37
112
28
77 64-90
66 55-77
-a
67
66
53-81
53 -79
84 75-93
52 37-67
73 63-83
62 46-78
73 63-83
62 47-77
85 76-94
54 40-68
87 80-94
30 10-50
81 74-88
25 5-45
Five year
P-value survival %
Relapse-free survival
95% CI P-value
55 38-72
NS 61 49-73
85
55
NS 55
<0.0546
NS
65 -
38 -
42-
NS
-105
-72
-68
71 59 -83
40 24-56
57 46-68
64 48-80
56 44-68
NS 64 49-79
0.0029
<0.0001
<0.0001
68 55-80
52 38-66
66 56-76
31 9-53
77 68-86
24
aFor overall survival analysis of the glottic tumour site was not included because very few events occurred
supraglottic P=0.059; glottic vs transglottic P=0.07; supraglottic vs transglottic P=NS.
0.0047
NS
NS
0.04
<0.049
2-46 <0.010
in this subgroup. bGlottic vs
Table III Multivariate analysis of prognostic variables for survival in primary laryngeal cancer patients
Prognostic variable
Age
<60 years
>60 years
Tumour site
Supraglottic
Transglottic
T classification
1 -2
3-4
Lymph node involvment
No
Yes
Histopathological grading
GI -G2
G3
Overall survival
RR 95% CI x2
Relapse-free survival
P-value RR 95% CI x2 P-value
2.30 1.02-5.16 4.11 0.0425 1.14 0.61 -2.14 1.19 0.27
0.44 0.20-0.94 4.40 0.0357 0.58 0.29- 1.16 2.31 0.12
4.75 2.06- 10.93 13.44 0.0002 2.73 1.36- 5.47 8.06 0.0045
1.85 0.88-3.87 2.69 0.10
2.93 1.38 -6.21 7.84 0.0051
1.00 0.50- 1.98 0.010 0.90
1.47 0.73-2.95 1.19 0.27
EGFR status
<20 fmol mg-' protein
>20 fmol mg-- protein 4.00 2.00-8.00 15.49
RR, relative risk taking into account all the factors of the table.
0.0001 2.17 1.17-4.02 6.11 0.0134PiFg-c rob dEGFR eve_ m y.s canew
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Experimental evidence showed a role of EGFR in the
development of laryngeal cancer. Our previous study
reported higher EGFR levels in laryngeal tumours than in
normal mucosa (Scambia et al., 1991) in accordance with
other authors (Santini et al., 1991). A significant correlation
between EGFR levels and stage was found in head and neck
cancer (Santini et al., 1991; Dassonville et al., 1993), whereas
we reported higher EGFR expression in poorly differentiated
(G3) than in well/moderately differentiated (G1-G2)
laryngeal tumours (Scambia et al., 1991).
To our knowledge, this is the first study analysing the
prognostic sigificnce of EGFR in a large prospective series
of laryngeal squamous cell carcinomas with a long follow-up
period. In our series the presence of high EGFR levels is
significantly correlated with a poor overall and relapse-free
survival. Moreover, analysis of logarithmically transformed
EGFR values shows that the risk of death and relapse
increases with increasing EGFR values in a significant way.
In the multivariate analysis, EGFR status retained an
independent prognostic role, suggesting that EGFR assess-
ment, together with clinical parameters, such as stage of
disease, may improve the prognostic characterisation of
laryngeal cancer patients. Our data are in accordance with
those of Dassonville et al. (1993) who reported a prognostic
role for EGFR in head and neck tumours, and with our
preliminary results on a smaller series of laryngeal cancer
(Maurizi et al., 1992).
This study suggests that the assessment of EGFR status at
the time of initial surgery may identify a subset of patients
with a particularly poor prognosis and permit therapy to be
modified accordingly. What is more, the prognostic
significance of EGFR levels might imply that laryngeal
cancer is a candidate for a novel anti-cancer therapy based on
drugs targeted directly against EGFR activity, such as anti-
EGFR monoclonal antibodies and the specific inhibitor of
the EGFR tyrosine kinase, which inhibit the growth ofcancer
ceRls in vitro and in vivo (Moreshige et al., 1991; Kurachi et
al., 1991; Schnurch et al., 1994; Fry et al., 1994).
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